Rezolute, Inc.
Rezolute Inc. (NASDAQ: RZLT) is a clinical stage biopharmaceutical company dedicated to developing transformative therapies for patients suffering from debilitating metabolic diseases. The lead asset is currently enrolling a Phase 3 registrational study in congential hyperinsulinism and seperately in tumor (associated) hyperinsulinism (hypoglycemia). Rezolute have received Break Through Designation for both indications by USFDA in 2025.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}